Sophia G Antimisiaris

Professor Antimisiaris' lab has extensive experience (more than 25 years) in design and production of liposomal and lipid/polymer/cyclodextrin hybrid nanoparticulates for drug and/or imaging agent delivery and targeting to specific target cells. Several administration routes have been investigated or are under investigation in regards to the specific requirements of liposomes for each specific route (such as: iv, ip, oral, lung/intrapleural, ocular/intravitreal, vaginal, etc.). Her laboratory...See more

Professor Antimisiaris' lab has extensive experience (more than 25 years) in design and production of liposomal and lipid/polymer/cyclodextrin hybrid nanoparticulates for drug and/or imaging agent delivery and targeting to specific target cells. Several administration routes have been investigated or are under investigation in regards to the specific requirements of liposomes for each specific route (such as: iv, ip, oral, lung/intrapleural, ocular/intravitreal, vaginal, etc.). Her laboratory also has long term collaborations with industries and is involved in development of new products. She has experience as coordinator and/or WP-leader in several large scale European Collaborative Projects, as Shiva (FP6), for development of liposomal microbicides for vaginal delivery, NAD (FP7, Nanoparticles for diagnosis and Therapy of AD), for design and development of liposomes s with affinity for Abeta peptides, SBR (Smart Bone Regeneration, H2020), for development of liposomal growth factors integrated in biomaterials. Her team have also been working for many years on the application of arsonolipid-containing liposomes for therapy of cancer with promising in vitro and in vivo results. They also investigate the development of novel platforms for sustained release of drugs following ocular/intravitreous, vaginal, intrapleural or subcutaneous administration. See less